Product Adoption Peytant Solutions' AMStent System is a platform technology featuring an amnion-based covered stent, with FDA De Novo clearance that signals regulatory validation for luminal disease treatment. The company has presented positive preclinical data for its tracheobronchial version, creating opportunities to engage interventional pulmonology and bronchoscopy programs, hospitals, and specialty centers with education and case-based evidence to drive adoption.

Leadership Growth Recent leadership hires including CEO Tom Douthitt (May 2026), Chief Medical Officer Craig Walker (2025), and Chief Commercial Officer JD Simpson (2025) indicate a strategic pivot toward commercial execution and clinical credibility. Use these executives to secure executive briefings with hospital systems, invite KOLs to advisory roles, and accelerate product training and onboarding for sales teams.

Regulatory Advantage FDA De Novo clearance for the AMStent System provides a credible regulatory foundation to support procurement and payer discussions. Position the platform as a first-in-class, human-derived membrane technology for luminal diseases, with potential for expanded indications as clinical evidence grows.

Strategic Partnerships Participation in industry events like AABIP and ongoing clinical development create openings for multi-center collaborations, academic partnerships, and strategic distributors. Target bronchoscopy and interventional pulmonology programs, research sites, and hospital networks to build pilots and evidence generation that can accelerate market penetration.

Scale Readiness Current revenue range and a lean team suggest sizable near-term growth potential through expanded sales, clinical education, and reimbursement strategies. Leverage the company’s platform approach to introduce additional indications; ramp field representation and digital marketing to reach hospitals and procurement teams.